% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hering:301912,
      author       = {S. Hering and R. Gaus and J. Hofmaier and S. Mansoorian and
                      S. Marschner and N.-S. Schmidt-Hegemann and V. d. S. Mendes
                      and A. Tufman and N. Reinmuth and G. Landry and M. Niyazi
                      and C. Belka$^*$ and S. Corradini and C. Eze},
      title        = {{P}rospective assessment of {MR}-guided single-fraction
                      stereotactic ablative radiotherapy for peripheral lung
                      metastases: dosimetric and clinical outcomes.},
      journal      = {Practical Radiation Oncology},
      volume       = {nn},
      issn         = {1879-8500},
      address      = {Amersterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-01182},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {This study aimed to evaluate the feasibility and safety of
                      online MR-guided single-fraction stereotactic ablative
                      radiotherapy (SABR) and to assess acute changes in pulmonary
                      function tests (PFTs), inflammatory markers,
                      patient-reported quality of life (QoL), and dosimetric
                      outcomes.Patients with lung metastases were included in this
                      single-center prospective study. Patients underwent
                      MR-guided single-fraction SABR. The primary endpoints
                      encompassed local control (LC) and overall survival (OS).
                      Secondary endpoints included acute toxicity (CTCAE v. 5.0),
                      changes in PFTs, inflammatory markers, QoL, and dosimetric
                      outcomes.Between 10/2020 and 10/2022, 26 patients with 30
                      lung metastases were prospectively enrolled. At a median
                      follow-up of 19.9 months (range: 16.1 - 25.6 months), the 1-
                      and 2-year LC rates were $96.2\%$ $(95\%$ CI: 88.7 -
                      $100.0\%)$ and $77.5\%$ $(95\%$ CI: 55.9 - $99.1\%).$ No
                      CTCAE grade 3+ side effects were observed. While there was a
                      slight median reduction of $4\%$ in forced expiratory volume
                      in 1 second (L) (p = 0.009, range: -24 - $20\%),$ other PFT
                      parameters remained stable. The neutrophil-to-lymphocyte
                      ratio increased by a median of $13\%$ (p = 0.002, range: -10
                      - $207\%),$ while serum C-reactive protein and albumin
                      levels remained unchanged. Patient-reported QoL did not
                      exhibit significant changes, except for a minimal increase
                      in the median score for cognitive functioning from 1 to 1.5
                      (p = 0.041).MR-guided single-fraction SABR is a safe and
                      effective treatment option for peripheral lung metastases,
                      demonstrating encouraging local control.},
      keywords     = {Single-fraction MR-guided stereotactic ablative
                      radiotherapy (Other) / health-related quality of life
                      (Other) / immunotherapy (Other) / lung cancer (Other) /
                      pulmonary function parameters (Other)},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40480627},
      doi          = {10.1016/j.prro.2025.05.006},
      url          = {https://inrepo02.dkfz.de/record/301912},
}